April 8, 2022

SARC032 Expanded
SU2C has made additional funds available for SARC032 so that we can increase the sample size and power of this randomized, ongoing trial from 102 to 126 evaluable patients. SARC032 …
Read moreSU2C has made additional funds available for SARC032 so that we can increase the sample size and power of this randomized, ongoing trial from 102 to 126 evaluable patients. SARC032 …
Read moreSARC is seeking a part-time Chief Medical Officer (CMO). The CMO (a newly created role for SARC) will work in partnership with the Chief Executive Officer (CEO) and Chief Scientific …
Read moreThank you for attending the 2021 SARC Semiannual Virtual Meeting on November 11, 2021. If you were not able to join the virtual event please view the agenda along with …
Read moreAn informational session for the SARC Career Development Award LOIs will be held Tuesday, November 30, 2021, noon – 1 pm ET. The session will be led by Dr. Jonathan …
Read moreANN ARBOR, MI October 22, 2021 – SARC (Sarcoma Alliance for Research Through Collaboration) is pleased to announce that Jonathan Fletcher, M.D., has been appointed Chief Scientific Officer (CSO), a …
Read moreSARC is pleased to announce our 2022 Career Development Award (CDA) funding opportunity. Past graduates (link here) of the SARC CDA program are pursuing productive independent careers at leading institutions …
Read moreSARC is pleased to announce that Dr. Jonathan Fletcher has been appointed Chief Scientific Officer. Dr. Fletcher is a lab-based medical and pediatric oncologist at Harvard Medical School, Brigham and Women’s …
Read moreSARC collaborator SFA is hosting a virtual Advocacy Day on July 21, 2021, during Sarcoma Awareness Month. If you would like to be a part of this day, or to learn …
Read moreThank you for attending the 2021 SARC Semiannual Virtual Meeting on June 4, 2021. If you were not able to join the virtual event please view the agenda along with …
Read more